|LETTER TO THE EDITOR
|Year : 2009 | Volume
| Issue : 3 | Page : 311-312
Cutaneous metastasis in prostatic carcinoma
Devender Pal, Vineet Talwar, DC Doval, YP Jalpota, Neeraj Kumar
Rajiv Gandhi Cancer Institute and Research Centre, Rohini Sector-5, New Delhi, India
Rajiv Gandhi Cancer Institute and Research Centre, Rohini Sector-5, New Delhi
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Pal D, Talwar V, Doval D C, Jalpota Y P, Kumar N. Cutaneous metastasis in prostatic carcinoma. Indian J Dermatol Venereol Leprol 2009;75:311-2
|How to cite this URL:|
Pal D, Talwar V, Doval D C, Jalpota Y P, Kumar N. Cutaneous metastasis in prostatic carcinoma. Indian J Dermatol Venereol Leprol [serial online] 2009 [cited 2020 May 26];75:311-2. Available from: http://www.ijdvl.com/text.asp?2009/75/3/311/51274
Almost all prostate cancers are adenocarcinoma. The age-specific mortality and absolute number of deaths from prostate cancer have been decreasing since 1993.  There is an almost 8:1 ratio in the incidence of prostate-specific mortality. The disease locally invades along the nerve sheath and metastasizes through lymphatic chains or blood vessels.  Distant metastases are common when lymph nodes are involved. Bone is the most common site of metastases. Here, we are reporting one patient with metastatic prostatic carcinoma who later developed cutaneous metastases during the course of disease.
A 50-year-old man presented with protuberant left eye (without any loss in visual acuity) and increased urinary frequency for the last 6 to 7 months. On examination, he had prostatomegaly, the biopsy of which showed adenocarcinoma of prostate with Gleason's score of 4+3. CT scan of the head revealed infiltrative lesions involving the left sphenoid bone and left orbit. He also had extensive bone and brain metastases on 99m TcDP whole-body bone scan. He was initially treated with bilateral orchiectomy, External Beam Radio Therapy (EBRT) to brain and was given radioactive phosphorous for bone metastases. He partially responded to the treatment and later received hormone therapy on relapse. Because of the recurrent disease, he received EBRT twice again for spinal/epidural disease. Subsequently, he presented with 3 small, fleshy, painless lesions on the right side of the forehead and bilateral parietooccipital region of the scalp, which were slowly increasing in size over the last 2 to 3 months. On examination, they were 1 × 0.8cm, 0.7 × 0.7cm and 0.5 × 0.5cm, non-tender and firm nodular lesions [Figure 1]. FNAC and, subsequently, biopsy of the skin lesions revealed malignant cells, with some of them forming glands with hyperchromatic nuclei and prominent nucleoli suggestive of cutaneous metastases of adenocarcinoma of the prostate [Figure 2] and [Figure 3]. They were found to be positive for PSA by immunohistochemical staining, thus confirming the prostatic origin of the skin lesions.
Between 2% and 9% of visceral malignancies are responsible for cutaneous metastases. , They usually occur in the advanced stage of malignancy and are associated with poor prognosis. Although carcinoma of the prostate is common, it is responsible for less than 1% of the skin metastases.  Also, skin metastases are a rare manifestation of prostatic adenocarcinoma. Skin metastases from prostate cancer are an ominous finding and most patients die within 6 months. The skin lesions are usually asymptomatic and lower abdomen, genitalia and thighs are most often involved.  The head region can also be involved, although rarely seen, as in our case. The lesions are usually papular and they rarely ulcerate. They may have zosteriform distribution or mimic pyoderma.  Occasionally, they appear as sclerodermoid lesion. 
The mechanism of skin involvement is not well understood  but suggested routes include embolization of vessels, dissemination via lymphatics  and spread through perineural lymphatics.
In most cases, where skin metastases have occurred, the primary cancer is widespread and may be advanced. Thus, the treatment is palliative care at this stage which includes keeping the lesion dry and clean. Debridement is an option for bleeding or crusting lesions.
| References|| |
|1.||Jemel A, Tiwari RC, Murry T. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8. |
|2.||Venable DD, Hastings D, Mistra RP. Unusual metastatic patterns of prostate adenocarcinoma. J Urol 1983;130:980-5 |
|3.||Rosen I. Cutaneous metastatis. Med Clin North Am 1980;64:885-900. |
|4.||Spencer PS, Helm TN. Skin metastasis in cancer patient. Cutis 1987;39:119-21. [PUBMED] |
|5.||Brownstein MH, Helwig EB. Metastatic tumors of skin. Cancer 1972;29:1298-307. [PUBMED] |
|6.||Jones C, Rosen T. Multiple red nodules on lower abdomen. Arch Dermatol 1992;128:1533-8. |
|7.||Stahl D, Veien NK. Cutaneous metastases simulating another dermatoses. Cutis 1980;26:282-4 [PUBMED] |
|8.||Pique-Duran E, Paradela A, Farina MC, Escalonilla P, Soriano ML, Olivares M, et al . Cutaneous metastasis from prostatic carcinoma. J Surg Oncol 1996;62:144-7. |
|9.||Marquis W, Benson R. Long term survival with skin metastasis from carcinoma of prostate. Urology 1980;16:407-8. [PUBMED] |
[Figure 1], [Figure 2], [Figure 3]
|This article has been cited by|
||Cutaneous metastasis of prostate carcinoma to neck and upper chest
| || Abrol, N., Seth, A., Chattergee, P. |
| ||Indian Journal of Pathology and Microbiology. 2011; 54(2): 394-395 |